Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory and toxic myopathies.

M C Dalakas1

  • 1Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

Current Opinion in Neurology and Neurosurgery
|October 1, 1992
PubMed
Summary

This review covers inflammatory myopathies, distinguishing polymyositis, dermatomyositis, and inclusion-body myositis. It explores viral associations and toxic myopathies from medications like zidovudine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations.

Lupus·2016
Same author

GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.

Journal of neuroimmunology·2015
Same author

7th International Immunoglobulin Conference: Interlaken Leadership Awards.

Clinical and experimental immunology·2014
Same author

7th International Immunoglobulin Conference: Interlaken Leadership Awards.

Clinical and experimental immunology·2014
Same author

Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis.

Journal of neuroimmunology·2013
Same author

Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study.

European journal of neurology·2012

Area of Science:

  • Neurology
  • Immunology
  • Pathology

Background:

  • Inflammatory myopathies encompass polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM).
  • Distinct diagnostic criteria are crucial for differentiating these conditions.
  • Understanding the pathogenesis of these myopathies is key to effective treatment.

Purpose of the Study:

  • To review recent advances in the immunopathogenesis and treatment of inflammatory myopathies.
  • To delineate the distinguishing features of PM, DM, and IBM.
  • To examine the role of viral infections and drug toxicities in myopathy development.

Main Methods:

  • Literature review of immunopathogenesis and treatment strategies.
  • Analysis of diagnostic criteria for differentiating PM, DM, and IBM.
  • Consideration of pathobiology, including amyloid and ubiquitin deposits in IBM.
  • Examination of viral (HIV, HTLV-I) and drug-induced (zidovudine, CLAM) myopathies.

Main Results:

  • Key differences between PM, DM, and IBM are highlighted.
  • The role of amyloid and ubiquitin deposits in IBM pathogenesis is discussed.
  • Human immunodeficiency virus (HIV) and human T-cell lymphotrophic virus (HTLV)-I associated PM pathogenesis is presented.
  • Toxic myopathies induced by zidovudine, cholesterol-lowering agents, and corticosteroid combinations are described.

Conclusions:

  • Accurate differentiation of inflammatory myopathies is essential for appropriate management.
  • Viral infections and certain medications can trigger distinct forms of myopathy.
  • Further research into immunopathogenesis and treatment is warranted for improved patient outcomes.

Related Experiment Videos